Results 71 to 80 of about 5,478,695 (241)

Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies

Experimental Hematology & Oncology
Background Chimeric antigen receptor engineered T cells (CAR-T) have demonstrated promising clinical efficacy in B-cell malignancies, and the approach has been extended to T-cell malignancies. However, the use of allogeneic T cells in CAR therapy poses a
Yingling Zu, Quan Ren, Jishuai Zhang, Hongchang Su, Qiumei Lu, Yongping Song, Jian Zhou   +6 more
doaj   +1 more source

ANTI-CD19 CARS ARMED WITH NK RECEPTOR-DERIVED ACTIVATION DOMAINS DEMONSTRATE TO IMPROVE CAR-NK ANTITUMOR EFFECTOR FUNCTION AND ARE DIFFERENTIALLY ENHANCED BY DASATINIB

Hematology, Transfusion and Cell Therapy, 2023
Natural Killer (NK) cells represent a cytotoxic group of cells that play important roles in immune surveillance and antitumor activities. They mediate the death of target cells through activating receptors in a Human Leukocyte Antigen (HLA)-unrestricted ...
MHD Santos, JTC Azevedo, RN Silvestre, RDT Calado, DT Covas, V Picanç-Castro   +5 more
doaj   +1 more source

Macrophage Trogocytosis of Tumor Cells Drives the Immunosuppression of Tumor Microenvironment

Advanced Science, EarlyView.
Trogocytosis efficiency varies significantly among different tumor cells and is inversely related to their cortical stiffness; this efficiency dictates the extent of immunosuppression via upregulation of CXCL5 and Arg‐1, ultimately driving CD8+T cell exhaustion and tumor escape.
Chao Liang, Jiaqi He, Wan‐Ru Zhuang, Yao Lei, Yanru Jiang, Xianbin Ma, Pan Liu, Zhujun Jiang, Yongheng Li, Hai‐Yan Xie   +9 more
wiley   +1 more source

Construction of anti-HER2 affibody-directed CAR-NK and its synergistic effects with doxorubicin-loaded nanodrug against HER2-positive breast cancer

Frontiers in Immunology
IntroductionChimeric antigen receptor (CAR)-engineered T or natural killer (NK) cells are a promising approach for cancer immunotherapy. The leading region of the CAR structure is generally a single-chain antibody (scFv) fragment specific for a tumor ...
Xuesong He, Xuesong He, Zhaoyuan Liang, Qing Liu, Xiaofei Zhang, Hao Liang, Runqing Jia, Wang Sheng   +7 more
doaj   +1 more source

The Efficacy of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) in NK-92 Cells, αβ T Cells, and γδ T Cells for B Cell Lymphoma (BCL) Cells

, 2023
Background: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy is effective in the treatment of relapsed or refractory aggressive B-cell lymphomas, but it can induce antigen-escape such as CD19low or CD19- malignant B cells and relapse.
한민아
core  

FOXP1 Knockdown Reprograms Th9 CAR‐T Cells to Overcome Antigen Escape

Advanced Science, EarlyView.
FOXP1 knockdown enhances Th9 CAR‐T cell function by promoting IL‐9 production, effector activation, and reduced exhaustion. Reprogrammed Th9 CAR‐T cells strengthen direct tumor killing and activate endogenous antitumor immunity through dendritic cells and CD8+ T cells, thereby suppressing both antigen‐positive and antigen‐loss tumor growth and ...
Yihan Zhu, Xingwei Xie, Xiaohuan Wu, Suidong Ouyang, Yang Zhou, Kang Wen, Yutong Zhong, Yuyang Chen, Handuo Wang, Yuan Gao, Ling Jiang, Hui Li, Wenli Zhao, Abai Xu, Enguang Bi   +14 more
wiley   +1 more source

Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges

Frontiers in Immunology
Chimeric antigen receptor-natural killer (CAR-NK) cell therapy is a novel immunotherapy targeting cancer cells via the generation of chimeric antigen receptors on NK cells which recognize specific cancer antigens. CAR-NK cell therapy is gaining attention
Jun Chang Kong, Mohammad Auwal Sa’ad, Mohammad Auwal Sa’ad, Hema Manusri Vijayan, Manickam Ravichandran, Manickam Ravichandran, Venugopal Balakrishnan, Seng Kong Tham, Gee Jun Tye   +8 more
doaj   +1 more source

Advances in CAR-NK cell therapy for hematological malignancies

Frontiers in Immunology
Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized the treatment of hematological malignancies, demonstrably improving patient outcomes and prognosis. However, its application has introduced new challenges, such as safety concerns, off-target toxicities, and significant costs.
Rui Yang, Yun Yang, Yun Yang, Rui Liu, Yiwen Wang, Ruoyu Yang, Aili He, Aili He   +7 more
openaire   +3 more sources

TP53 Loss Elevates NF‐κB‐IFN‐β‐MHC‐Ia Signaling to Promote NK Cell Resistance in Osteosarcoma

Advanced Science, EarlyView.
TP53 loss in a transforming or osteosarcoma cell promotes cytosolic DNA accumulation, activating NF‐κB‐dependent IFN‐β production. Autocrine IFN‐β signaling increases cell‐surface HLA‐Ia expression, strengthens inhibitory KIR signaling in natural killer cells, and thereby enables the affected cell to evade NK cell‐mediated cytotoxicity.
Guihui Qin, Cheung Kwan Yeung, Ye Yi, Dejin Zheng, Miaoman Ye, Chi‐Chong Chio, Jinjie Wu, Siyi Fu, Chu‐Xia Deng, Ren‐He Xu   +9 more
wiley   +1 more source

Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy

MedComm, 2023
Chimeric antigen receptor (CAR) T cells have been successfully used in adoptive cell therapy for malignancies. However, some obstacles, including side effects such as graft‐versus‐host disease and cytokine release syndrome, therapy resistance, limited ...
Yan Wang, Shengjie Jin, Qiqi Zhuang, Na Liu, Ruyi Chen, Sofia Abdulkadir Adam, Jie Jin, Jie Sun   +7 more
doaj   +1 more source